INREBIC Trademark Registration for Pharmaceutical Preparations
Summary
USPTO registered trademark TM86690908 for INREBIC on March 30, 2026. The mark covers pharmaceutical preparations for treatment of beta thalassemia, myelodysplastic syndromes, blood diseases, cancer, and cytokine inhibitory drugs. Originally filed July 13, 2015.
What changed
USPTO issued a trademark registration for INREBIC (Registration No. TM86690908) covering pharmaceutical preparations for therapeutic use in beta thalassemia, myelodysplastic syndromes, blood diseases, cancer, and cytokine inhibitory drugs. The trademark was filed on July 13, 2015, and reached registered status on March 30, 2026.
Pharmaceutical companies and drug manufacturers should note this trademark registration when developing branding strategies for similar therapeutic products. The registration provides the trademark holder with federal protection in Class 5 (pharmaceuticals) and may be used to enforce against confusingly similar marks in the pharmaceutical space. No immediate compliance actions are required, but companies should ensure their product branding does not infringe on this registered mark.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
← USPTO Trademark Applications
INREBIC
Registered TM86690908 Kind: registered Mar 30, 2026
Abstract
Pharmaceutical preparations for use in the treatment of beta thalassemia and myelodsplatic syndromes, [ autoinflammatory disease, autoimmune disease, ] blood disease, cancer, [ arthritis, musculoskeletal and skin diseases in the fields of oncology, immunology and inflammation; ] pharmaceutical preparations, namely, cytokine inhibitory drugs; [ pharmaceutical preparations that modulate the immune system ]
Filing Date
2015-07-13
Related changes
Get daily alerts for USPTO Trademarks - Pharmaceuticals (Class 005)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Trademarks - Pharmaceuticals (Class 005) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.